N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) for predicting silent myocardial ischaemia in type 2 diabetes mellitus independent of microalbuminuria

2010 ◽  
Vol 26 (7) ◽  
pp. 534-539 ◽  
Author(s):  
Kumiko Hamano ◽  
Mariko Abe ◽  
Rieko Komi ◽  
Shuzo Kobayashi
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Myocardial Ischaemia ◽  
Silent Myocardial Ischaemia ◽  
Terminal Fragment

scholarly journals A. Diagnostic and prognostic value of detection of the N-terminal fragment of brain natriuretic peptide in type 2 diabetes mellitus

2017 ◽  
Vol 95 (6) ◽  
pp. 553-557
Author(s):  
A. F. Verbovoy ◽  
Natal’ya A. Barabanova
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Blood Glucose ◽  
Chronic Heart Failure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Terminal Fragment

Detction of chronic heart failure at the stage of reversible changes can prevent the development of cardiovascular complications, reduce morbidity and mortality in patients with type 2 diabetes mellitus. The aim of our study was to explore the level of N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) and to evaluate the possibility of using this marker in diagnostics of chronic heart failure in patients with type 2 diabetes. The study included 60 patients with type 2 diabetes and concomitant chronic heart failure. All patients underwent echocardiography, blood glucose and glycated hemoglobin, creatinine, and NT-proBNP measurement. All patients with diabetes mellitus were shown to have elevated NT-proBNP levels in comparison with the control group. We established negative correlation of this parameter with the left ventricular ejection fraction and inverse correlation between NT-proBNP and blood glucose. The study confirmed the value of NT-proBNP measurement for diagnostics of CHF but demonstrated low specificity of this test for the assessment of severity (functional class) of CHF in patients with type 2 diabetes.

Fibrinogen is associated with silent myocardial ischaemia in type 2 diabetes mellitus

2009 ◽  
Vol 64 (4) ◽  
pp. 523-530 ◽  
Author(s):  
R. Guardado- Mendoza ◽  
L. Jimenez-Ceja ◽  
M.F. Pacheco-Carrasco ◽  
A. Aguayo-Godinez ◽  
J. Molina-Padilla ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Myocardial Ischaemia ◽  
Silent Myocardial Ischaemia

Prognostic role of brain natriuretic peptide (BNP) levels in patients with type 2 diabetes mellitus

2004 ◽  
Vol 10 (4) ◽  
pp. S48
Author(s):  
Meenakshi A. Bhalla ◽  
Audrey Chiang ◽  
Victoria A. Epshteyn ◽  
Radmila Kazanegra ◽  
Vikas Bhalla ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Prognostic Role

scholarly journals NT-pro brain natriuretic peptide in patients with type 2 diabetes mellitus without overt heart failure: a hospital based cross sectional study

2021 ◽  
Vol 8 (4) ◽  
pp. 563
Author(s):  
Sanjay Varma ◽  
Archana Toppo ◽  
Khagdev Ram ◽  
Rajeev Lochan Khare ◽  
Yogendra Malhotra ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Brain Natriuretic Peptide ◽  
Diastolic Dysfunction ◽  
Natriuretic Peptide ◽  
Age Group ◽  
Cross Sectional

Background: Increased secretion of brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) occurs mainly with increased tension in the ventricular walls, decreased oxygen supply, acute myocardial infarction, chronic cardiac heart failure, and in hypertrophy of the heart. Objective was to find out the prevalence and profile of NT-pro BNP levels in patients with type 2 diabetes mellitus (DM) without overt heart failure.Methods: Hospital based cross sectional observational study was conducted in the Department of Medicine, Pt. JNM Medical College and associated Dr. BRAM Hospital Raipur, Chhattisgarh involving 106 patients of type 2 DM during the period of April 2019 to April 2020, after ethical approval from institutional ethical committee.Results: The levels of NT pro BNP was found to be elevated in 87.7% patients of DM type 2. Majority of them were from 51-60 years age group (35.5%). Elevated NT proBNP levels was seen in 23.58% of patients having grade I diastolic dysfunction, 3.7% patients with grade II diastolic dysfunction and 1.88% patients having grade III diastolic dysfunction on echocardiography out of the 106 patients. Regardless of presence of diastolic dysfunction on echo, 93 (87.73%) patients out of the total study group of 106 patients had elevated BNP suggesting cardiac dysfunction. In the present study, 30.19% patients with diabetes were found to have varying degrees of diastolic dysfunction on echocardiography.Conclusions: The prevalence of elevated NT pro BNP was 87.7%. Commonly observed age group with elevated NT pro BNP was 51-60 years. NT pro BNP was elevated in 88.7% of males and in 88.36% of females. Prevalence of elevated NT pro BNP was higher in grade 1 diastolic dysfunction with DM duration of more than 5 years (33.3%). Higher prevalence of elevated NT pro BNP was seen in grade I diastolic dysfunction (23.58%). 

scholarly journals The Effect of Omega-3 Polyunsaturated Fatty Acids on N-Terminal Pro-Brain Natriuretic Peptide and Lipids Concentration in Patients With Type 2 Diabetes Mellitus and Cardiovascular Autonomic Neuropathy

2014 ◽  
Vol 21 (2) ◽  
pp. 97-101 ◽  
Author(s):  
Victoria Serhiyenko ◽  
Alexandr Alexandr Serhiyenko ◽  
Volodymyr Segin
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Fatty Acids ◽  
Type 2 Diabetes Mellitus ◽  
Polyunsaturated Fatty Acids ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Autonomic Neuropathy ◽  
Long Chain

Abstract Background and Aims: Cardiac autonomic neuropathy (CAN) in type 2 diabetes mellitus (T2DM) is one of the independent risk factor for cardiovascular mortality. The aim of the study was to analyze the effect of long-chain w-3 polyunsaturated fatty acids (w-3 PUFA) on the levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) and on some lipid profile parameters in patients with T2DM and CAN. Material and Methods: 36 patients with T2DM and verified CAN were divided into 2 groups. The first group received traditional hypoglycemic therapy (n = 15, control) for three months; patients in group 2 (n = 21) received in addition 1 g/day of the long-chain w-3 PUFA for three months. Results: Prescription of the w-3 PUFA to the patients with T2DM and СAN was accompanied by a statistically significant decrease of NT-proBNP level and led to significantly positive changes in the high density lipoprotein cholesterol and triglycerides levels in the blood. Conclusions: Obtained results suggest that the efficacy of w-3 PUFA is the result of a direct effect of the pharmacological agent on the investigated indexes

Sign in / Sign up

Export Citation Format

Share Document